AKTX/ 07/20/2026 · 1:13 PM Akari Therapeutics Strengthens Balance Sheet and Prepares Phase 1 as Maxim Raises Rating to Buy Backed by promising Trop2 ADC preclinical data, new financing, and strong ADC market momentum.
